1-(3,4-Methylenedioxyphenyl)-2-propylaminopentane (MPAP), also known as 3,4-methylenedioxy-α,N-dipropylphenethylamine, N-propyl-1,3-benzodioxolylpentanamine (PDBP), or propyl-K, is a monoaminergic activity enhancer (MAE) of the phenethylamine, amphetamine, and α-propylphenethylamine families that is closely related to phenylpropylaminopentane (PPAP).

[1] Like PPAP and BPAP, but in contrast to amphetamines, MPAP has no classical monoamine releasing agent actions.

[1] MPAP has comparable potency to PPAP and selegiline as a MAE in terms of enhancing the monoamine neurotransmitters in the isolated rat brain stem ex vivo.

[1] However, it was 5-fold more potent than PPAP and selegiline as a MAE in rodents in vivo in terms of the minimum dose that significantly antagonized the behavioral depression induced by tetrabenazine in the shuttle box.

[1] The effects of MAEs seem to be mediated by intracellular TAAR1 agonism coupled with uptake by monoamine transporters into monoaminergic neurons.